Recentin cediranib: Phase III data

Top-line data from the double-blind, international Phase III HORIZON II trial in 1,050 first-line mCRC patients showed that Recentin plus FOLFOX or XELOX chemotherapy met the co-primary endpoint of significantly improving PFS vs. placebo plus FOLFOX or XELOX, but missed the OS co-primary endpoint. In March, the pharma reported that Recentin plus FOLFOX missed the primary endpoint of non-inferiority to Avastin bevacizumab plus FOLFOX in PFS in the Phase II/III HORIZON III trial for the indication (see BioCentury, March 15). Based on the results from the 2 trials, AstraZeneca said it does not intend to submit regulatory applications for Recentin to treat first-line mCRC. ...